EMD · ASX

Emyria Ltd (ASX:EMD)

AU$0.033

 0.0 (0.0%)
ASX:Live
19/03/2025 12:50:37 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EMD Overview

EMD Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About EMD

Website

Emyria Ltd

Telephone

61.13.0043.6363

Address

D2 661 Newcastle Street Leederville, Western Australia (WA) 6007

Description

Emyria Ltd. is a healthcare technology and services company. It operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from informed and consenting patients. The company was founded on March 19, 2018 and is headquartered in Leederville, Australia.

EMD Price Chart

Key Stats

Market Cap

AU$15.27M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.07

Trade Value (12mth)

AU$3,206.00

1 week

-5.71%

1 month

-5.71%

YTD

-8.33%

1 year

-45%

All time high

0.50

Key Fundamentals

EPS 3 yr Growth

43.00%

EBITDA Margin

-281.80%

Operating Cashflow

-$4m

Free Cash Flow Return

-85.30%

ROIC

-228.10%

Interest Coverage

-24.50

Quick Ratio

0.90

Other Data

Shares on Issue (Fully Dilluted)

421m

HALO Sector

Technology

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EMD Announcements

Latest Announcements

Date Announcements

05 March 25

Application for quotation of securities - EMD

×

Application for quotation of securities - EMD

05 March 25

Notification regarding unquoted securities - EMD

×

Notification regarding unquoted securities - EMD

05 March 25

Section 708A(5)(e) Notice

×

Section 708A(5)(e) Notice

27 February 25

Appendix 4D and Half Year End Financial Report

×

Appendix 4D and Half Year End Financial Report

14 February 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

14 February 25

Letter to Shareholders - Notice of General Meeting

×

Letter to Shareholders - Notice of General Meeting

04 February 25

Emyria Reports Promising 3-Month PTSD Treatment Results

×

Emyria Reports Promising 3-Month PTSD Treatment Results

04 February 25

Euroz Hartleys 2025 Healthcare Forum Presentation

×

Euroz Hartleys 2025 Healthcare Forum Presentation

31 January 25

December 2024 Quarterly Activities Report and Appendix 4C

×

December 2024 Quarterly Activities Report and Appendix 4C

22 January 25

Leadership Updates

×

Leadership Updates

12 December 24

Application for quotation of securities - EMD

×

Application for quotation of securities - EMD

12 December 24

Section 708A(5)(e) Notice

×

Section 708A(5)(e) Notice

27 November 24

Emyria Secures $2.525M in Strongly Supported Placement

×

Emyria Secures $2.525M in Strongly Supported Placement

27 November 24

Proposed issue of securities - EMD

×

Proposed issue of securities - EMD

25 November 24

Trading Halt

×

Trading Halt

25 November 24

Investor Update - November 2024

×

Investor Update - November 2024

15 November 24

Notification of cessation of securities - EMD

×

Notification of cessation of securities - EMD

12 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

12 November 24

Response to ASX Price Query

×

Response to ASX Price Query

31 October 24

Emyria & UWA Partner to License Novel Serotonin Therapies

×

Emyria & UWA Partner to License Novel Serotonin Therapies

31 October 24

Proposed issue of securities - EMD

×

Proposed issue of securities - EMD

30 October 24

September 2024 Quarterly Activities Report and Appendix 4C

×

September 2024 Quarterly Activities Report and Appendix 4C

28 October 24

Emyria Gains Ethics Endorsement for Psilocybin Program

×

Emyria Gains Ethics Endorsement for Psilocybin Program

11 October 24

Annual Report

×

Annual Report

11 October 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

EMD Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.02 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.02 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.4 35.2 -80.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.8 31.6 38.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.8 -10.6 -30.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -50.9 -96.8 112.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 269 289 359 Lock Lock Lock
Basic m Lock Lock Lock Lock 269 289 359 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.8 -12.6 38.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 4 4 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -4 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -178.6 24.8 14.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -242.2 -208.6 -128.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 342 309 229 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -7 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.9 17.6 7.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -447.1 -421.8 -281.8 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -7 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.5 16.6 3.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -468.5 -447.0 -313.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -7 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -7 -5 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.4 30.0 -123.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -402.1 -322.2 -520.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -4 -4 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 3 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 -3 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 5 6 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -4 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.9 30.9 -17.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3.0 -2.4 -2.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 4 3 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 8 10 5 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -3 -1 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 6 7 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 7 7 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.7 3.7 -55.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -88.8 -50.5 -211.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -115.9 -75.5 -472.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -113.2 -94.8 -113.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -100.3 -75.4 -228.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -74.3 -55.4 -85.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -112.8 -52.2 -24.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.4 0.2 -0.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -51.4 -21.5 6.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.8 0.9 0.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.8 0.9 0.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 94.3 95.8 81.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -373.0 -119.8 -191.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 10.1 18.4 37.9 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.7 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 34.0 70.5 22.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.2 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.2 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -465.9 -453.4 -634.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -102.9 -71.0 -257.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -88.8 -50.5 -211.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.5 2.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -115.9 -75.5 -472.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -115.9 -75.5 -472.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 36.1 19.8 9.6 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 36.1 19.8 9.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 25.3 64.7 58.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 10.8 -44.9 -49.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EMD Shortsell

Frequently Asked Questions

The current share price of Emyria Ltd (EMD:ASX) is AU$0.033.
The 52-week high share price for Emyria Ltd (EMD:ASX) is AU$0.07.
The 52-week low share price for Emyria Ltd (EMD:ASX)? is AU$0.03.
Emyria Ltd (EMD:ASX) does not pay a dividend.
Emyria Ltd (EMD:ASX) does not pay a dividend.
Emyria Ltd (EMD:ASX) has a franking level of 0.0%.
Emyria Ltd (EMD:ASX) is classified in the Technology.
The current P/E ratio for Emyria Ltd (EMD:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.